Literature DB >> 24126503

[Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].

C Protzel1, A K Seitz, O W Hakenberg, M Retz.   

Abstract

Data on the treatment of advanced penile carcinoma especially for chemotherapy are very limited. Due to the results of recent studies there has been a shift to taxan/cisplatinum based regimens. Initial case reports also showed a response to targeted therapy especially antibodies against epidermal growth factor receptor (EGFR). Nevertheless, a curative treatment by medicinal approaches alone does not appear to be possible for metastatic penile cancer and can be only cured by multimodal approaches, including neoadjuvant and adjuvant chemotherapy and salvage lymph node dissection. Palliative chemotherapy of advanced penile cancer has to be individually adapted and weighed against best supportive care for the final decision.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24126503     DOI: 10.1007/s00120-013-3252-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  33 in total

1.  Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.

Authors:  G P Haas; B A Blumenstein; R G Gagliano; C A Russell; S E Rivkin; D J Culkin; M Wolf; E D Crawford
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

Review 2.  [Penile cancer--aftercare with results. How much is necessary?].

Authors:  R Paul; H van Randenborgh; S Schöler; F May; R Hartung
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

3.  Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy.

Authors:  J Kattan; S Culine; J P Droz; E Fadel; B Court; J L Perrin; P Wibault; C Haie-Meder
Journal:  Urology       Date:  1993-11       Impact factor: 2.649

Review 4.  Advanced penile carcinoma.

Authors:  Daniel J Culkin; Tomasz M Beer
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

5.  Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.

Authors:  A M Hussein; P Benedetto; K S Sridhar
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

Review 6.  Lymphadenectomy in the surgical management of penile cancer.

Authors:  Chris Protzel; Antonio Alcaraz; Simon Horenblas; Giorgio Pizzocaro; Alexandre Zlotta; Oliver W Hakenberg
Journal:  Eur Urol       Date:  2009-02-23       Impact factor: 20.096

7.  A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

Authors:  C Theodore; I Skoneczna; I Bodrogi; M Leahy; J M Kerst; L Collette; K Ven; S Marréaud; R D T Oliver
Journal:  Ann Oncol       Date:  2008-04-15       Impact factor: 32.976

8.  cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study.

Authors:  R G Gagliano; B A Blumenstein; E D Crawford; R L Stephens; C A Coltman; J J Costanzi
Journal:  J Urol       Date:  1989-01       Impact factor: 7.450

Review 9.  Targeted therapies in squamous cell carcinoma of the head and neck.

Authors:  Kathryn A Gold; Ho-Young Lee; Edward S Kim
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

10.  Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma.

Authors:  Hong-Feng Gou; Xiang Li; Meng Qiu; Ke Cheng; Long-Hao Li; Hang Dong; Ye Chen; Yuan Tang; Feng Gao; Feng Zhao; Hai-Tao Men; Jun Ge; Jing-Mei Su; Feng Xu; Feng Bi; Jian-Jun Gao; Ji-Yan Liu
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.